Keyphrases
Parkinson's Disease
68%
Non-motor Symptoms
39%
Parkinson Patients
39%
2-year Follow-up
30%
Levodopa-carbidopa Intestinal Gel
26%
Quality of Life
24%
Advanced Parkinson's Disease
23%
Symptom Burden
21%
Motor Fluctuations
16%
Patients with Parkinson's Disease
12%
Early Parkinson's Disease
11%
Comparisons with a Control
11%
Cerebrospinal Fluid
10%
Intestinal Gel
10%
Multiple System Atrophy
10%
Impulse Control Disorders
10%
Non-motor
10%
Unified Parkinson's Disease Rating Scale (UPDRS)
9%
Cognitive Impairment
9%
Dyskinesia
8%
Activities of Daily Living
8%
Sleep Quality
7%
Fluid Level
7%
Levodopa
7%
Adverse Events
6%
Spain
6%
Clinically Significant
6%
Motor Severity
6%
Motor Symptoms
6%
Visual Hallucinations
5%
Catalan
5%
Barcelona
5%
Decoppering
5%
Ammonium Tetrathiomolybdate
5%
Neurological Symptoms
5%
Wilson Disease
5%
Psychopathological
5%
Diplopia
5%
Long-term Response
5%
Hypomimia
5%
123I-FP-CIT SPECT
5%
Disease Impact
5%
Long-term Efficacy
5%
Compulsive Behavior
5%
Disease Imaging
5%
Functional Independence
5%
Brain Correlates
5%
Leucine-rich Repeat Kinase 2 (LRRK2)
5%
Huntington's Disease
5%
Comorbid Factors
5%
Neuroscience
Parkinson's Disease
100%
Non-Motor Symptoms
27%
Carbidopa/Levodopa
21%
L-DOPA
13%
Huntington's Disease
10%
Impulse Control Disorder
10%
Multiple System Atrophy
10%
Cognitive Disorders
7%
Single-Photon Emission Computed Tomography
7%
Dopaminergic
6%
Visual Hallucination
5%
Comorbidity
5%
Diplopia
5%
Sleep Quality
5%
Coenzyme
5%
In Vivo
5%
Adverse Effect
5%
Compulsive Behavior
5%
Iodine-123
5%
Cholinergic
5%
Basal Forebrain
5%
